CRSP vs. EDIT
CRSP (CRISPR Therapeutics AG) and EDIT (Editas Medicine, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, CRSP returned -16.09%/yr vs -40.59%/yr for EDIT. A 0.66 correlation means they provide meaningful diversification when combined.
Performance
CRSP vs. EDIT - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CRSP achieves a 3.66% return, which is significantly lower than EDIT's 36.59% return.
CRSP
- 1D
- 0.50%
- 1M
- 7.94%
- YTD
- 3.66%
- 6M
- -6.13%
- 1Y
- 22.85%
- 3Y*
- -1.00%
- 5Y*
- -16.09%
- 10Y*
- —
EDIT
- 1D
- 4.09%
- 1M
- 1.45%
- YTD
- 36.59%
- 6M
- 20.17%
- 1Y
- 26.13%
- 3Y*
- -29.73%
- 5Y*
- -40.59%
- 10Y*
- -20.00%
CRSP vs. EDIT - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
CRSP CRISPR Therapeutics AG | 3.66% | 33.23% | -37.12% | 54.00% | -46.36% | -50.51% | 151.39% | 113.18% | 21.68% | 15.89% |
EDIT Editas Medicine, Inc. | 36.59% | 61.42% | -87.46% | 14.21% | -66.59% | -62.13% | 136.78% | 30.15% | -25.97% | 89.34% |
Correlation
The correlation between CRSP and EDIT is 0.65, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.65 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.67 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.70 |
Correlation (All Time) Calculated using the full available price history since Oct 19, 2016 | 0.66 |
The correlation between CRSP and EDIT has been stable across timeframes, ranging from 0.65 to 0.70 - a consistent structural relationship.
Fundamentals
CRSP:
$5.22B
EDIT:
$274.06M
CRSP:
-$6.24
EDIT:
-$1.21
CRSP:
1.21K
EDIT:
7.05
CRSP:
2.88
EDIT:
62.17
CRSP:
$4.10M
EDIT:
$35.86M
CRSP:
-$171.17M
EDIT:
$35.86M
CRSP:
-$509.21M
EDIT:
-$76.66M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CRSP vs. EDIT — Risk / Return Rank
CRSP
EDIT
CRSP vs. EDIT - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for CRISPR Therapeutics AG (CRSP) and Editas Medicine, Inc. (EDIT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CRSP | EDIT | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.09 | ||
| Sortino ratioReturn per unit of downside risk | -0.16 | ||
| Omega ratioGain probability vs. loss probability | 1.11 | 1.13 | -0.02 |
| Calmar ratioReturn relative to maximum drawdown | 0.54 | 0.44 | +0.10 |
| Martin ratioReturn relative to average drawdown | 0.89 | 0.76 | +0.12 |
Loading charts...
Drawdowns
CRSP vs. EDIT - Drawdown Comparison
The maximum CRSP drawdown since its inception was -85.11%, smaller than the maximum EDIT drawdown of -98.92%. Use the drawdown chart below to compare losses from any high point for CRSP and EDIT.
Loading charts...
Drawdown Indicators
| CRSP | EDIT | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -85.11% | -98.92% | +13.81% |
Max Drawdown (1Y)Largest decline over 1 year | -42.25% | -59.88% | +17.63% |
Max Drawdown (3Y)Largest decline over 3 years | -64.91% | -91.18% | +26.27% |
Max Drawdown (5Y)Largest decline over 5 years | -80.68% | -98.66% | +17.98% |
Max Drawdown (10Y)Largest decline over 10 years | — | -98.92% | — |
Current DrawdownCurrent decline from peak | -74.12% | -96.91% | +22.79% |
Average DrawdownAverage peak-to-trough decline | -49.29% | -62.70% | +13.41% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 25.88% | 34.43% | -8.55% |
Volatility
CRSP vs. EDIT - Volatility Comparison
The current volatility for CRISPR Therapeutics AG (CRSP) is 17.92%, while Editas Medicine, Inc. (EDIT) has a volatility of 32.47%. This indicates that CRSP experiences smaller price fluctuations and is considered to be less risky than EDIT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CRSP | EDIT | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 17.92% | 32.47% | -14.55% |
Volatility (6M)Calculated over the trailing 6-month period | 43.95% | 62.15% | -18.20% |
Volatility (1Y)Calculated over the trailing 1-year period | 62.70% | 93.67% | -30.97% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 60.72% | 94.22% | -33.50% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 64.31% | 83.85% | -19.54% |
Dividends
CRSP vs. EDIT - Dividend Comparison
Neither CRSP nor EDIT has paid dividends to shareholders.
Financials
CRSP vs. EDIT - Financials Comparison
This section allows you to compare key financial metrics between CRISPR Therapeutics AG and Editas Medicine, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
CRSP and EDIT have a correlation of 0.65, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
EDIT has higher volatility (32.47%) compared to CRSP (17.92%). In terms of maximum drawdown, CRSP dropped -85.11% vs EDIT's -98.92%.
CRSP currently has the higher Sharpe Ratio (0.37 vs 0.28), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CRSP and EDIT
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer